Morphologic Substrates of Cognitive Impairment in Parkinson Disease

Central nervous system lesions contributing to cognitive impairment in PD are heterogeneous, including dysfunction of subcortico-cortical (striato-subfrontal, cholinergic fore-brain) networks due to neuronal loss in brainstem and limbic areas, cholinergic deficits in cortical regions and thalamus, associated with decreased striatal dopaminergic function,^10,11 widespread decrease of nicotinic acetylcholine receptors,¹² and, in particular, limbic and cortical LB and Alzheimer pathologies with loss of synapses and neurons,^2,6,13–¹⁵ presynaptic αSyn aggregates causing synaptic dysfunction,¹⁶ or variable combinations of these changes that may have common origins with mutual triggering due to suggested synergistic reactions between αSyn, amyloid peptide and tau protein, the major protein markers of both LB diseases and AD.^9,17–²⁰ Although a few cortical LBs are found in virtually all cases of sporadic PD (brainstem type of LB disease), the impact of cortical LB and AD pathologies on cognitive impairment in PD is a matter of discussion. Recent studies have demonstrated that the number of LBs in the frontal gyri is the most significant predictor of cognitive status in PD,²¹ and that LB densities in the limbic cortex are a better predictor of dementia in PD than Alzheimer-type pathology.²²–²⁴ Some authors demonstrated increasing cognitive decline (with decreasing MMSE scores) with increasing LB stages from 3 to 6, i.e. progression of αSyn pathology,¹⁴ while others have not found such an association.^9,25–²⁹ In an autopsy series of 330 elderly patients with clinical parkinsonism (37.6% of which with dementia), only 1.6% of the demented patients (MMSE<20) showed LB Braak stages 3–5, which was found in the majority of non-demented PD cases, while 35.5% of demented PD cases revealed morphologic LB stages 4 or 5 with superimposed severe Alzheimer-type pathology (neuritic Braak stages 5 and 6). More than half of them showed a strong relationship between the severity of αSyn and tau pathologies, particularly in the limbic system. DLB with low or high-grade Alzheimer lesions were seen in 40% of PDD patients, but almost one-third of diffuse DLB cases, i.e. those with mild AD lesions restricted to amyloid plaques or tau pathology in the limbic system, did not show considerable dementia.⁶ Neuropathology revealed lower brain weight in PDD than in the two other groups, and significantly more severe Alzheimertype pathology (neuritic Braak stages, cortical amyloid plaque load and generalized cerebral amyloid angiopathy, CAA) in PDD and DLB than in non-demented PD cases, while the LB scores were moderately increased in PDD and highest in DLB. Significantly increased amyloid plaque load in the cerebral cortex in PDD and DLB is in agreement with previous studies,³⁰–³³ whereas others did not find any correlation between cortical Aβ deposition and cognitive impairment in DLB.³⁴ Increase of amyloid load in meningeal and cortical vessels (CAA) in both PDD and DLB is also in agreement with previous studies.^35,36 In general, significant association between cortical amyloid plaque load, general CAA and neuritic Braak stages, the latter increasing with age, is observed, suggesting an influence of Alzheimer-related pathology on the progression of the neurodegenerative process and, in particular, on cognitive decline in both PDD and DLB. On the other hand, both these factors in PD and DLB appear to be largely independent from coexisting vascular pathology, except in cases with severe cerebrovascular lesions or those related to neuritic Alzheimer pathology.⁹

Morphologic Comparison between Parkinson Disease Dementia and Dementia with Lewy Bodies

The neuropathology of PDD and DLB shows similarities and slight differences. The morphology and immunohisto-chemistry of cortical and subcortical LBs and the ascending spreading pattern of αSyn pathology with onset in the lowe brainstem and progression via midbrain, dorsal forebrain, amygdala limbic system to the neocortex³⁷ do not signficantly differ between both phenotypes, the late stages 5 and 6 of LB pathology (involvement of sensory association and prefrontal primary sensory and motor areas) suggesting transition between PD and DLB.² However, there are some deviations between DLB and PDD in the severity and distribution pattern of lesions in substantia nigra compacta (less severe damage in DLB involving dorsolateral versus medioventral nuclei in PD) and more frequent αSyn pathology in the hippocampal subarea C 2/3 in DLB (79 vs. 36%). A major difference is the usually more frequent severe diffuse amyloid plaque load and less severe tau pathology in the striatum in DLB cases, irrespective of the severity of cortical neuritic Alzheimer lesions, while non-demented PD cases are virtually free of striatal amyloid plaque load.^38,39 The question, whether PD, PDD and DLB are different disorders or represent a single entity with distinct clinical and pathologic phenotypes is still considered controversially, while some genetic and biochemical differences argue for a separation between DLB/PDD and AD.² Recent studies indicating synergistic interactions between αSyn, amyloid peptide and tau protein, common markers for both PD and AD, and the frequent co-occurrence of these pathologies³¹ suggest common underlying mechanisms inducing both neurodegeneration and fibrillary protein aggregation that are typical of these disease processes (double or triple amyloidosis^40), but it is unclear whether these lesions represent different pathogentic pathways or a final pathology leading to neuronal degeneration causing both movement disorders and dementia. The molecular background and clinical/pathophysiological impact of these and other pathologies on the progression and development of cognitive impairment in PD and other LB disorders remain to be further elucidated.

REFERENCES

• 1. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113:421–429.ArticlePubMed
• 2. Jellinger KA. Lewy body disorders. In: Youdin MBH, Riederer P, Mandel SA, Battistin L, Lajtha A, editors. Degenerative Diseases of the Nervous System. Springer Science New York: 2007a:267–343.Article
• 3. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–1872.ArticlePubMed
• 4. Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 2008;67:125–143.ArticlePubMed
• 5. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22:1689–1707.quiz 1837.. ArticlePubMed
• 6. Jellinger KA. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J Neural Transm Suppl 2007;91–104.ArticlePubMed
• 7. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34:561–566.ArticlePubMed
• 8. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4:428–430.ArticlePubMed
• 9. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008;115:427–436.ArticlePubMed
• 10. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716–1722.ArticlePubMed
• 11. Ziabreva I, Ballard CG, Aarsland D, Larsen JP, McKeith IG, Perry RH, et al. Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging 2006;27:433–438.ArticlePubMed
• 12. Fujita M, Ichise M, Zoghbi SS, Liow JS, Ghose S, Vines DC, et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease. Ann Neurol 2006;59:174–177.ArticlePubMedPMC
• 13. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 2005;58:773–776.ArticlePubMed
• 14. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404–1410.ArticlePubMed
• 15. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006;67:1605–1611.ArticlePubMed
• 16. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405–1410.ArticlePubMedPMC
• 17. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449–458.ArticlePubMed
• 18. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008;115:409–415.ArticlePubMed
• 19. Lashley T, Holton JL, Gray E, Kirkham K, O’Sullivan SS, Hilbig A, et al. Cortical alpha-synuclein load is associated with amyloidbeta plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol in press:. 10.1007/s00401-00007-00336-00400. 2008;115:417–425.ArticlePubMed
• 20. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 2006;31:1153–1162.ArticlePubMed
• 21. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 2000;100:285–290.ArticlePubMed
• 22. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102–112.ArticlePubMed
• 23. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000;54:1916–1921.ArticlePubMed
• 24. Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol 2003;106:83–88.ArticlePubMed
• 25. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:852–856.ArticlePubMedPMC
• 26. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001;102:355–363.ArticlePubMed
• 27. Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 2002;109:329–339.ArticlePubMed
• 28. Jellinger KA. Re: In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2008;70:407–408.ArticlePubMed
• 29. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007;69:356–359.ArticlePubMed
• 30. Barrachina M, Dalfó E, Puig B, Vidal N, Freixes M, Castan̈o E, Ferrer I. Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor. Neurochem Int 2005;46:253–260.ArticlePubMed
• 31. Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 2006;65:278–288.ArticlePubMed
• 32. Jendroska K, Lees AJ, Poewe W, Daniel SE. Amyloid beta-peptide and the dementia of Parkinson’s disease. Mov Disord 1996;11:647–653.ArticlePubMed
• 33. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord 2003;18:81–86.ArticlePubMed
• 34. Thomas A, Ballard C, Kenny RA, O’Brien J, Oakley A, Kalaria R. Correlation of entorhinal amyloid with memory in Alzheimer’s and vascular but not Lewy body dementia. Dement Geriatr Cogn Disord 2005;19:57–60.ArticlePubMed
• 35. Mastaglia FL, Masters CL, Beyreuther K, Kakulas BA. Deposition of Alzheimer’s disease amyloid (A4) protein in the cerebral cortex in Parkinson’s disease. Prog Clin Biol Res 1989;317:475–484.PubMed
• 36. Wu E, Lipton RB, Dickson DW. Amyloid angiopathy in diffuse Lewy body disease. Neurology 1992;42:2131–2135.ArticlePubMed
• 37. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.ArticlePubMed
• 38. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006;112:253–260.ArticlePubMed
• 39. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155–161.ArticlePubMed
• 40. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008;65:184–189.ArticlePubMed

Figure & Data

References

Citations

Citations to this article as recorded by  

• The neuropathologic substrate of Parkinson disease dementia
  Kurt A. Jellinger
  Acta Neuropathologica.2010; 119(1): 151.     CrossRef

Comments on this article